Literature DB >> 1500267

Phase II evaluation of piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study.

A Allen1, M Wolf, E D Crawford, M P Davis, R B Natale, M L Barnett.   

Abstract

The Southwest Oncology Group (SWOG) studied the response rate and toxicity of piroxantrone (150 mg/m2 q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 32 eligible patients, there were no partial nor complete responses. There were two mixed responses. Significant white cell toxicity, anemia, nausea, and vomiting were observed. Mild or moderate degrees of fever, malaise, and stomatitis occurred. No significant cardiac toxicity was noted. Piroxantrone does not have significant activity as a single agent in advanced renal cell carcinoma.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1500267     DOI： 10.1007/bf00873131

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  5 in total

1.  In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles).

Authors:  D W Fry; T J Boritzki; J A Besserer; R C Jackson
Journal:  Biochem Pharmacol       Date:  1985-10-01       Impact factor: 5.858

2.  Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole).

Authors:  M M Ames; C L Loprinzi; J M Collins; C van Haelst-Pisani; R L Richardson; J Rubin; C G Moertel
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

3.  Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to those of doxorubicin.

Authors:  B V Clarke; K V Harwood; R Donehower
Journal:  J Natl Cancer Inst       Date:  1989-09-06       Impact factor: 13.506

4.  Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors.

Authors:  W R Leopold; J M Nelson; J Plowman; R C Jackson
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

5.  Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.

Authors:  A Hantel; R C Donehower; E K Rowinsky; E Vance; B V Clarke; W P McGuire; D S Ettinger; D A Noe; L B Grochow
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701
  5 in total
  2 in total

1.  Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.

Authors:  M M Zalupski; J Benedetti; S P Balcerzak; L F Hutchins; R J Belt; A Hantel; J W Goodwin
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

2.  Phase II trial of piroxantrone in metastatic breast cancer. A Southwest Oncology Group study.

Authors:  P M Ravdin; S Green; J H Doroshow; S Martino
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.